Lixisenatide is a recombinant DNA produced polypeptide analogue of human glucagon -like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 …

Lixisenatide (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of …

ChemSpider record containing structure, synonyms, properties, vendors and database links for lixisenatide, 320367-13-3, XVVOERDUTLJJHN-IAEQDCLQSA-N

Lixisenatide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist mimicking several favorable actions of endogenous GLP-1 that result in improved glycemic control with little or no …

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Lixisenatide, a glucagon-like peptide-1 receptor agonist, is used to stimulate insulin secretion in patients with type 2 diabetes mellitus.

2006年11月20日 · Lixisenatide is a 44-amino-acid peptide that is amidated at the C-terminal amino acid having structural similarity with exendin-4 [71]. Because kidneys are the major …

Lixisenatide (structure shown in Figure 1) is a synthetically produced polypeptide that is a potent and selective GLP-1 receptor agonist. It is structurally similar to GLP -1 as well as exenatide, …

2023年11月27日 · Visit ChemicalBook for more information on Lixisenatide (CAS 827033-10-3), including its chemical and physical properties, structure, melting point, boiling point, density, …

2025年1月5日 · Lixisenatide (brand name Adlyxin) is used to improve blood sugar (glucose) control in adults with type 2 diabetes when used with diet and exercise. Lixisenatide is a GLP …